Correction to: Efficacy and Safety Results from a Phase 2, Randomized, Double Blind Study of Enzalutamide Versus Placebo in Advanced Hepatocellular Carcinoma.

Ryoo, Baek-Yeol; Palmer, Daniel H; Park, Sook Ryun; Rimassa, Lorenza; Sarker, Debashis; Daniele, Bruno; Steinberg, Joyce; López, Beatriz; Lim, Ho Yeong

Ryoo, Baek-Yeol; Palmer, Daniel H; Park, Sook Ryun; Rimassa, Lorenza; Sarker, Debashis; Daniele, Bruno; Steinberg, Joyce; López, Beatriz; Lim, Ho Yeong.

Afiliación

Ryoo BY; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. ryooby@amc.seoul.kr.
Palmer DH; Liverpool CR UK/NIHR Experimental Cancer Medicine Centre, and The Clatterbridge Cancer Centre, Liverpool, UK.
Park SR; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Rimassa L; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
Sarker D; Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Daniele B; School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.
Steinberg J; Department of Oncology, G. Rummo Hospital, Benevento, Italy.
López B; Oncology Unit, Ospedale del Mare, Naples, Italy.
Lim HY; Astellas Pharma Inc., Northbrook, IL, USA.

Clin Drug Investig ; 42(3): 283, 2022 Mar.

Article en En | MEDLINE | ID: mdl-35220556

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Clin Drug Investig Asunto de la revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2022 Tipo del documento: Article País de afiliación: Corea del Sur

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google